228 results on '"Flies, Dallas"'
Search Results
2. Leukocyte-associated immunoglobulin-like receptor-1 blockade in combination with programmed death-ligand 1 targeting therapy mediates increased tumour control in mice
3. Author Correction: Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability
4. LAIR-1 agonism as a therapy for acute myeloid leukemia
5. Up-regulated PLA2G10 in cancer impairs T cell infiltration to dampen immunity
6. The FLRT3-UNC5B checkpoint pathway inhibits T cell–based cancer immunotherapies
7. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-[beta] signaling enables PD-L1-mediated tumor eradication
8. Regulation of tumor immunity and immunotherapy by the tumor collagen extracellular matrix
9. Supplementary Figure FS2 from Quantitative, Spatially Defined Expression of Leukocyte-associated Immunoglobulin-like Receptor in Non–small Cell Lung Cancer
10. Data from Quantitative, Spatially Defined Expression of Leukocyte-associated Immunoglobulin-like Receptor in Non–small Cell Lung Cancer
11. Supplementary Table TS1 from Quantitative, Spatially Defined Expression of Leukocyte-associated Immunoglobulin-like Receptor in Non–small Cell Lung Cancer
12. Data from CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
13. Supplemental Figure 2 from CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
14. Supplemental Figure 1 from CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
15. Supplemental Figure 3 from CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer
16. Supplementary Figure 1 from Blockade of B7-H1 and PD-1 by Monoclonal Antibodies Potentiates Cancer Therapeutic Immunity
17. Quantitative, Spatially Defined Expression of Leukocyte Associated Immunoglobulin-like Receptor (LAIR-1) in Non-Small Cell Lung Cancer
18. A Phase 1, Open-Label, Safety, Tolerability, and Efficacy Study of NC525 in Subjects with Advanced Myeloid Neoplasms
19. 739 A phase 1b/2, open-label, safety, tolerability and efficacy study of NC410 plus pembrolizumab for participants with immune checkpoint inhibitor (ICI) refractory, or MSS/MSI-low ICI naïve advanced or metastatic solid tumors
20. 748 A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC762 in subjects with advanced or metastatic solid tumors
21. Programmed death one homolog maintains the pool size of regulatory T cells by promoting their differentiation and stability
22. Remodeling the tumor microenvironment via blockade of LAIR-1 and TGF-β signaling enables PD-L1–mediated tumor eradication
23. A Novel Lair-1 Antibody Selectively Targets Acute Myeloid Leukemia (AML) Stem Cells
24. 570 Blockade of the inhibitory collagen receptor LAIR-1, PD-L1, and TGF-β promotes anti-tumor activity through T cell activation and myeloid cell polarization
25. 487 NC410, a fusion protein of LAIR-2 (Leukocyte Associated Immunoglobulin-like Receptor) with human IgG1 Fc, is safe & tolerable with evidence of immune modulation in subjects with advanced solid tumors
26. Collagen Fragments Produced in Cancer Mediate T Cell Suppression Through Leukocyte-Associated Immunoglobulin-Like Receptor 1
27. Coinhibitory receptor PD-1H preferentially suppresses [CD4.sup.+] T cell-mediated immunity
28. Abstract 3193: Development and functional characterization of NC762, a novel therapeutic antibody targeting B7-H4, for the treatment of malignancies
29. Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction
30. Author response: Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR-collagen interaction
31. 445 Blockade of the inhibitory collagen receptor LAIR-1 with NC410, a LAIR2-Fc fusion protein, enhances anti-tumor activity of the bifunctional fusion protein bintrafusp alfa
32. 694 NC410 is a novel immunomedicine for the treatment of solid tumors
33. Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking LAIR-collagen interaction
34. Strain-specific induction of experimental autoimmune prostatitis (EAP) in mice
35. B7-H2 Is a Costimulatory Ligand for CD28 in Human
36. Rapid tumor vaccine using Toll-like receptor-activated ovarian cancer ascites monocytes
37. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway
38. PD-1H (VISTA)–mediated suppression of autoimmunity in systemic and cutaneous lupus erythematosus
39. Androgen ablation mitigates tolerance to a prostate/prostate cancer-restricted antigen
40. Essential role of TNF family molecule LIGHT as a cytokine in the pathogenesis of hepatitis
41. Ligation of CD137 receptor prevents and reverses established anergy of CD8+cytolytic T lymphocytes in vivo
42. Role of LAG-3 in Regulatory T Cells
43. B7-H1 Determines Accumulation and Deletion of Intrahepatic CD8+ T Lymphocytes
44. B7-H4, a Molecule of the B7 Family, Negatively Regulates T Cell Immunity
45. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis
46. Provision of antigen and CD137 signaling breaks immunological ignorance, promoting regression of poorly immunogenic tumors
47. Reassessment of CD62L as a marker of pre-effector T cells in the tumor draining lymph nodes of head and neck cancer patients
48. Blockade of LIGHT/LTβ and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease
49. Siglec-15 as an immune suppressor and potential target for normalization cancer immunotherapy
50. Cancer immunotherapy by NC410, a LAIR-2 Fc protein blocking human LAIR- collagen interaction.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.